New treatment targets for the management of irritable bowel syndrome

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 21, Issue 1, 2014, Pages 9-14

  Rao, Supriya ^a   Weber, H Christian ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

chronic idiopathic constipation; gastrointestinal receptors; irritable bowel syndrome (IBS); linaclotide; lubiprostone; serotonin

Indexed keywords

CHLORIDE CHANNEL; FATTY ACID DERIVATIVE; GUANYLATE CYCLASE; LINACLOTIDE; LUBIPROSTONE; PEPTIDE DERIVATIVE; SEROTONIN AGONIST; SEROTONIN ANTAGONIST;

CONSTIPATION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HEALTH CARE COST; HUMAN; IRRITABLE COLON; NONHUMAN; QUALITY OF LIFE; REVIEW;

ALPROSTADIL; CONSTIPATION; FEMALE; GASTROINTESTINAL AGENTS; GASTROINTESTINAL MOTILITY; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; PEPTIDES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN RECEPTOR AGONISTS; TREATMENT OUTCOME;

EID: 84892371611     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0000000000000034     Document Type: Review

References (75)

1. El-Salhy M. Irritable bowel syndrome: Diagnosis and pathogenesis. WJG 2012; 18: 5151-5163
2. El-Salhy M, Seim I, Chopin L, et al. Irritable bowel syndrome: The role of gut neuroendocrine peptides. Front Biosci (Elite Ed) 2012; 4: 2783-2800
3. Quigley EM, Abdel-Hamid H, Barbara G, et al. A global perspective on irritable bowel syndrome: A consensus statement of the World Gastroenterology Organisation Summit Task Force on irritable bowel syndrome. J Clin Gastroenterol 2012; 46: 356-366
4. Mayer EA. Clinical practice. Irritable bowel syndrome. N Engl J Med 2008; 358: 1692-1699
5. Agarwal N, Spiegel BM. The effect of irritable bowel syndrome on healthrelated quality of life and healthcare expenditures. Gastroenterol Clin North Am 2011; 40: 11-19
6. Spiegel B, Harris L, Lucak S, et al. Developing valid and reliable health utilities in irritable bowel syndrome: Results from the IBS PROOF Cohort. Am J Gastroenterol 2009; 104: 1984-1991
7. Martin BC, Ganguly R, Pannicker S, et al. Utilization patterns and net direct medical cost to Medicaid of irritable bowel syndrome. Curr Med Res Opin 2003; 19: 771-780
8. Leong SA, Barghout V, Birnbaum HG, et al. The economic consequences of irritable bowel syndrome: A US employer perspective. Arch Intern Med 2003; 163: 929-935
9. Longstreth GF, Wilson A, Knight K, et al. Irritable bowel syndrome, healthcare use, and costs: A U.S. managed care perspective. Am J Gastroenterol 2003; 98: 600-607
10. Camilleri M, Williams DE. Economic burden of irritable bowel syndrome. Proposed strategies to control expenditures. Pharmacoeconomics 2000; 17: 331-338
11. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006; 130: 1480-1491
12. Elsenbruch S, Holtmann G, Oezcan D, et al. Are there alterations of neuroendocrine and cellular immune responses to nutrients in women with irritable bowel syndrome? Am J Gastroenterol 2004; 99: 703-710
13. Ringel Y, Sperber AD, Drossman DA. Irritable bowel syndrome. Annu Rev Med 2001; 52: 319-338
14. Chang L. Neuroendocrine and neuroimmune markers in IBS: Pathophysiological role or epiphenomenoñGastroenterology 2006; 130: 596-600
15. Feng B, La JH, Schwartz ES, Gebhart GF. Irritable bowel syndrome: Methods, mechanisms, and pathophysiology. Neural and neuro-immune mechanisms of visceral hypersensitivity in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2012; 302: G1085-G1098
16. Spiller R. Serotonergic agents and the irritable bowel syndrome: What goes wrong? Curr Opin Pharmacol 2008; 8: 709-714
17. Park JH, Rhee PL, Kim G, et al. Enteroendocrine cell counts correlate with visceral hypersensitivity in patients with diarrhoea-predominant irritable bowel syndrome. Neurogastroenterol Motil 2006; 18: 539-546
18. Camilleri M. Peripheral mechanisms in irritable bowel syndrome. N Engl J Med 2012; 367: 1626-1635
19. Yoon SL, Grundmann O, Koepp L, Farrell L. Management of irritable bowel syndrome (IBS) in adults: Conventional and complementary/alternative approaches. Altern Med Rev 2011; 16: 134-151
20. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104 (Suppl 1): S1-S35
21. Clouse RE, Lustman PJ, Geisman RA, Alpers DH. Antidepressant therapy in 138 patients with irritable bowel syndrome: A five-year clinical experience. Alimen Pharmacol Ther 1994; 8: 409-416
22. Gershon MD. 5-Hydroxytryptamine (serotonin) in the gastrointestinal tract. Curr Opin Endocrinol Diab Obes 2013; 20: 14-21
23. Gershon MD, Tack J. The serotonin signaling system: From basic understanding to drug development for functional GI disorders. Gastroenterology 2007; 132: 397-414
24. Weber HC. Gastrointestinal regulatory peptides. Curr Opin Endocrinol Diab Obes 2011; 18: 33-34
25. Blackshaw LA, Brierley SM. Emerging receptor target in the pharmacotherapy of irritable bowel syndrome with constipation. Expert Rev Gastroenterol Hepatol 2013; 7: 15-19
26. Camilleri M. Review article: New receptor targets for medical therapy in irritable bowel syndrome. Alimen Pharmacol Ther 2010; 31: 35-46
27. Ford AC, Brandt LJ, Young C, et al. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: Systematic review and meta-Analysis. Am J Gastroenterol 2009; 104: 1831-1843
28. Johnston JM, Shiff SJ, Quigley EM. A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation. Curr Med Res Opin 2013; 29: 149-160
29. Lacy BE, Chey WD. Lubiprostone: Chronic constipation and irritable bowel syndrome with constipation. Expert Opin Pharmacother 2009; 10: 143-152
30. Sainsbury A, Ford AC. Treatment of irritable bowel syndrome: Beyond fiber and antispasmodic agents. Ther Adv Gastroenterol 2011; 4: 115-127
31. Ford AC, Talley NJ. IBS in 2010: Advances in pathophysiology, diagnosis and treatment. Nature reviews. Gastroenterol Hepatol 2011; 8: 76-78
32. Talley NJ. Serotoninergic neuroenteric modulators. Lancet 2001; 358: 2061-2068
33. Tack J, Coulie B, Wilmer A, et al. Actions of the 5-hydroxytryptamine 1 receptor agonist sumatriptan on interdigestive gastrointestinal motility in man. Gut 1998; 42: 36-41
34. Andresen V, Montori VM, Keller J, et al. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptomrelief and constipation in nonconstipated irritable bowel syndrome: A systematic review and meta-Analysis of randomized controlled trials. Clin Gastroenterol Hepatol 2008; 6: 545-555
35. Spiller RC. Targeting the 5-HT(3) receptor in the treatment of irritable bowel syndrome. Curr Opin Pharmacol 2011; 11: 68-74
36. Lewis JH. Alosetron for severe diarrhea-predominant irritable bowel syndrome: Safety and efficacy in perspective. Expert Rev Gastroenterol Hepatol 2010; 4: 13-29
37. Nakai A, Diksic M, Kumakura Y, et al. The effects of the 5-HT3 antagonist, alosetron, on brain serotonin synthesis in patients with irritable bowel syndrome. Neurogastroenterol Motil 2005; 17: 212-221
38. Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: A meta-Analysis of randomized controlled trials. Neurogastroenterol Motil 2003; 15: 79-86
39. Balfour JA, Goa KL, Perry CM. Alosetron. Drugs 2000; 59: 511-518
40. Lewis JH. The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies. Drug Saf 2011; 34: 545-565
41. Chang L, Chey WD, Harris L, et al. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: Systematic review of clinical trials and postmarketing surveillance data. Am J Gastroenterol 2006; 101: 1069-1079
42. Cremonini F, Nicandro JP, Atkinson V, et al. Randomised clinical trial: Alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS. Alimen Pharmacol Ther 2012; 36: 437-448
43. Evans BW, Clark WK, Moore DJ, Whorwell PJ. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Cochrane Database Syst Rev 2007; CD003960
44. Kale-Pradhan PB, Wilhelm SM. Tegaserod for constipation-predominant irritable bowel syndrome. Pharmacotherapy 2007; 27: 267-277
45. Patel S, Berrada D, Lembo A. Review of tegaserod in the treatment of irritable bowel syndrome. Expert Opin Pharmacother 2004; 5: 2369-2379
46. Scott LJ, Perry CM. Tegaserod. Drugs 1999; 58: 491-496
47. Pasricha PJ. Desperately seeking serotonin. A commentary on the withdrawal of tegaserod and the state of drug development for functional and motility disorders. Gastroenterology 2007; 132: 2287-2290
48. http: //www.accessdata.fda.gov/drugsatfda-docs/label/2012/ 021908s010lbl.pdf [accessed 8 November 2013
49. Lubiprostone (amitiza) for chronic constipation. Med Lett Drugs Ther 2006; 48: 47-48
50. Lubiprostone: RU 0211, SPI 0211. Drugs R D. 2005;6(4): 245-8. Review. PubMed PMID: 15991886
51. Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: Lubiprostone in patients with constipation-Associated irritable bowel syndrome-results of two randomized, placebo-controlled studies. Alimen Pharmacol Ther 2009; 29: 329-341
52. Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: A double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Alimen Pharmacol Ther 2007; 25: 1351-1361
53. Fukudo S, Hongo M, Kaneko H, Ueno R. Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: A randomized, placebo-controlled and dose-finding study. Neurogastroenterol Motil 2011; 23: 544-e205
54. Chey WD, Drossman DA, Johanson JF, et al. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Alimen Pharmacol Ther 2012; 35: 587-599
55. Hyman PE, Di Lorenzo C, Prestridge LL, et al. An open-label, multicenter, safety and effectiveness study of lubiprostone for the treatment of functional constipation in children. J Pediatr Gastroenterol Nutrition 2013. [Epub ahead of print]. PubMed PMID: 24048162
56. Whitehead WE, Palsson OS, Gangarosa L, et al. Lubiprostone does not influence visceral pain thresholds in patients with irritable bowel syndrome. Neurogastroenterol Motil 2011; 23: 944-e400
57. Cuppoletti J, Blikslager AT, Chakrabarti J, et al. Contrasting effects of linaclotide and lubiprostone on restitution of epithelial cell barrier properties and cellular homeostasis after exposure to cell stressors. BMC Pharmacol 2012; 12: 3
58. Sherid M, Sifuentes H, Samo S, et al. Lubiprostone induced ischemic colitis. WJG 2013; 19: 299-303
59. Musch MW, Wang Y, Claud EC, Chang EB. Lubiprostone decreases mouse colonic inner mucus layer thickness and alters intestinal microbiota. Dig Dis Sci 2013; 58: 668-677
60. Chamberlain SM, Rao SS. Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome. Expert Opin Drug Saf 2012; 11: 841-850
61. Linaclotide (Linzess) for constipation. Med Letter Drugs Ther 2012; 54: 91-92; PubMed PMID: 23183319
62. Bharucha AE, Waldman SA. Taking a lesson from microbial diarrheagenesis in the management of chronic constipation. Gastroenterology 2010; 138: 813-817
63. Brierley SM. Guanylate cyclase-C receptor activation: Unexpected biology. Curr Opin Pharmacol 2012; 12: 632-640
64. Busby RW, Bryant AP, Bartolini WP, et al. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur J Pharmacol 2010; 649: 328-335
65. Busby RW, Kessler MM, Bartolini WP, et al. Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. J Pharmacol Exp Ther 2013; 344: 196-206
66. Andresen V, Camilleri M, Busciglio IA, et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation- predominant irritable bowel syndrome. Gastroenterology 2007; 133: 761-768
67. Johnston JM, Kurtz CB, Macdougall JE, et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology 2010; 139: 1877-1886 e1872
68. Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med 2011; 365: 527-536
69. Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012; 107: 1714-1724
70. Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: A 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012; 107: 1702-1712
71. Rao SS, Quigley EM, Shiff SJ, et al. Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation. Clin Gastroenterol Hepatol 2013; 11: 1984-1092
72. Quigley EM, Tack J, Chey WD, et al. Randomised clinical trials: Linaclotide phase 3 studies in IBS-C-A prespecified further analysis based on European Medicines Agency-specified endpoints. Alimen Pharmacol Ther 2013; 37: 49-61
73. Videlock EJ, Cheng V, Cremonini F. Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: A metaanalysis. Clin Gastroenterol Hepatol 2013; 11: 1084-1092e 1083
74. Feng B, Kiyatkin ME, La JH, et al. Activation of guanylate cyclase-C attenuates stretch responses and sensitization of mouse colorectal afferents. J Neurosci 2013; 33: 9831-9839
75. Castro J, Harrington AM, Hughes PA, et al. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-c and extracellular cyclic guanosine 30,50-monophosphate. Gastroenterology 2013. doi: 10.1053/j.gastro.2013.08.017. [Epub ahead of print